Skip directly to content

Mechanism of Action

Mechanism of Action

BESPONSA is designed to maximise efficacy and minimise toxicity in relapsed/refractory ALL by linking a targeted anti-CD22 monoclonal antibody (MoAb) with a potent cytotoxic payload. 1,2

ADC, antibody-drug conjugate; ALL, acute lymphoblastic leukaemia

Please view the following videos for more information on the mechanism of action.

Professor David Marks discusses the MoA of BESPONSA.
  1. BESPONSA® Prescribing Information. Pfizer Corporation Hong Kong Limited. Version Nov 2018.
  2. Shor B, Gerber H, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2):107-116. doi:10.1016/j.molimm.2014.09.014